HC Wainwright Issues Optimistic Forecast for AVBP Earnings

ArriVent BioPharma, Inc. (NASDAQ:AVBP) – HC Wainwright boosted their Q1 2025 earnings per share estimates for ArriVent BioPharma in a research note issued on Wednesday, January 22nd. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.78) per share for the quarter, up from their prior forecast of ($0.81). HC Wainwright currently has a “Buy” rating and a $39.00 price target on the stock. The consensus estimate for ArriVent BioPharma’s current full-year earnings is ($2.74) per share. HC Wainwright also issued estimates for ArriVent BioPharma’s Q2 2025 earnings at ($0.84) EPS, Q3 2025 earnings at ($0.88) EPS, Q4 2025 earnings at ($0.91) EPS and FY2025 earnings at ($3.41) EPS.

ArriVent BioPharma Stock Up 2.3 %

ArriVent BioPharma stock opened at $27.25 on Friday. ArriVent BioPharma has a 52 week low of $14.35 and a 52 week high of $36.37. The stock has a 50-day moving average price of $26.99 and a 200 day moving average price of $25.97.

Institutional Investors Weigh In On ArriVent BioPharma

A number of institutional investors and hedge funds have recently modified their holdings of AVBP. Rhumbline Advisers lifted its holdings in shares of ArriVent BioPharma by 30.1% during the second quarter. Rhumbline Advisers now owns 12,707 shares of the company’s stock worth $236,000 after purchasing an additional 2,942 shares during the period. Novo Holdings A S lifted its holdings in shares of ArriVent BioPharma by 39.3% during the second quarter. Novo Holdings A S now owns 1,500,000 shares of the company’s stock worth $27,825,000 after purchasing an additional 422,860 shares during the period. SG Americas Securities LLC purchased a new position in ArriVent BioPharma during the third quarter valued at approximately $280,000. Charles Schwab Investment Management Inc. raised its position in ArriVent BioPharma by 153.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 202,368 shares of the company’s stock valued at $4,756,000 after acquiring an additional 122,641 shares in the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new position in ArriVent BioPharma during the third quarter valued at approximately $240,000. Institutional investors and hedge funds own 9.48% of the company’s stock.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.